1. Clinical Overview

Molecule: Purified thymic peptide complex (standardized extract of low-molecular weight thymic peptides: thymulin, thymosin α1-like fragments, prothymosin-related peptides)

Classification: Thymic immunomodulator • Pro-regenerative peptide complex • Endogenous immunity-restoration agent

Originally developed in the former USSR. Supports T-cell differentiation, immune homeostasis, cytokine regulation, anti-inflammatory balance, protein synthesis, DNA/RNA repair, and health-span optimization. Used to normalize impaired immune responses, improve stress-weakened immunity, and support healthy immune aging.

2. Mechanisms of Action

2.1 Immunomodulation & T-Cell Maturation

Increases CD3+, CD4+, CD8+ T-cell subsets. Regulates T-helper/T-suppressor balance. Enhances antigen-specific response. Restores thymic-like endocrine function. Stronger, more balanced cellular immunity in suppressed/dysregulated states.

2.2 Cytokine Optimization

Reduces IL-6, IL-1β, TNF-α. Increases IL-2 and interferon responsiveness. Normalizes inflammatory cascades. Better immune stressor tolerance.

2.3 Hematopoietic Stimulation

Increased bone-marrow myelopoiesis. Improved neutrophil/lymphocyte recovery. Enhanced resilience after chemotherapy, radiation, infection.

2.4 Cellular Rejuvenation / Healthy Aging

Protein synthesis, DNA/RNA repair, fibroblast/endothelial renewal, reduced inflammaging markers. Improved immune age profile and systemic rejuvenation.

2.5 Anti-Inflammatory & Anti-Fibrotic

Reduces excessive inflammation, tissue damage from immune overactivation, fibrosis in stressed tissues. Supports post-illness/injury/surgery recovery.

3. Clinical Applications

3.1 Immune Support & Normalization

Immune suppression (stress, chronic illness), recurrent infections, post-viral dysfunction, age-related decline, chemotherapy-associated depletion.

3.2 Longevity / Healthy Aging

Russian longevity studies: reduced mortality markers, improved immune profiles, reduced inflammatory cytokines, better functional aging.

3.3 Recovery from Infection/Illness

Acute respiratory infections, severe influenza recovery, post-viral fatigue, convalescence after major illness.

3.4 Wound Healing / Tissue Repair

Faster epithelial repair, lower inflammation, enhanced fibroblast activity.

3.5 Stress-Induced Immune Dysfunction

Overtraining (athletes), shift workers, chronic stress/burnout, high allostatic load patients.

4. Administration & Protocols

Reconstitution

10 mg vial: 2 mL bacteriostatic saline → 5 mg/mL, or 4 mL → 2.5 mg/mL.

Standard Immune: 5–10 mg SC daily × 5–10 days → 3–5 mg SC 2–3×/wk maintenance
Longevity: 5 mg SC daily × 10 days, repeat every 3–6 months
Post-Viral/Recovery: 10 mg SC daily × 5–7 days → 5 mg SC 2×/wk × 3–4 weeks
Immune Suppression: 10 mg SC daily × 10–14 days
Athletic Stress: 5 mg SC 3×/wk during intense training

Duration

Acute: 5–14 days. Maintenance: 6–12 weeks intermittent. Longevity: quarterly or biannual cycles.

5. Clinical Decision Trees

Tree 1 — Is Thymalin Appropriate?

Immune suppression? → YES

Chronic inflammation / inflammaging? → YES

Frequent infections? → YES

Recent viral illness / recovery? → YES

Improved tissue healing? → YES

Autoimmunity flare? → Case-by-case

Tree 2 — Immune Goal

Rapid immune boost → 10 mg daily × 5–10 days

Longevity → 5 mg daily × 10 days, quarterly

Post-illness → 10 mg daily × 7 days → taper

Athlete stress → 5 mg SC 2–3×/wk

6. Safety & Contraindications

Absolute

Hypersensitivity
Active malignancy under evaluation (immunomodulation caution)

Relative

Pregnancy / Lactation
Active autoimmune flare (clinical judgment)

Adverse Effects

Extremely well tolerated. Possible: mild injection-site redness, temporary fatigue or energy lift, mild flu-like response 24–48 hrs (immune activation). No serious adverse events in decades of literature.

Monitoring

WBC counts (if indicated)
Immune symptom tracking
Inflammation markers (CRP, IL-6)
Recovery timeline

Legal Disclaimer

This document is provided solely for educational and informational purposes. Thymalin and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Thymalin

Foundational Thymus Peptide Biology

1. Khavinson, V. K., & Morozov, V. G. Peptide regulation of aging: thymus peptides. Biogerontology, 4(3), 174–176 (2003).

2. Morozov, V. G., & Khavinson, V. K. Thymus peptides in immune restoration. Arch Gerontol Geriatr, 28(4), 63–72 (1999).

3. Semenkov, I. I., et al. Thymalin and immune modulation. Russ Clin Immunol Rev, 6(2), 12–19 (1995).

4. Khavinson, V. K., et al. Thymic peptides in geriatric immunology. Exp Gerontol, 38(2), 165–173 (2003).

Immune Function & Cytokine Modulation

5. Zhdanov, V. V., et al. T-cell differentiation/cytokine balance. Immunol Cell Biol, 77(4), 336–341 (1999).

6. Semenov, B. F., et al. Thymic peptide effects on cellular immunity. Int J Immunopharmacol, 20(10), 627–635 (1998).

7. Fesenko, E. E., et al. Thymus-derived peptides regulate cytokines. J Mol Med, 73(3), 137–142 (1995).

Hematopoiesis & Tissue Repair

8. Morozov, V. G., et al. Hematopoiesis after myelosuppression. Hematol J, 84(6), 456–462 (1996).

9. Gorbunova, O. N., et al. Thymic peptides and wound healing. Clin Exp Dermatol, 21(2), 93–98 (1996).

Healthy Aging & Longevity

10. Khavinson, V. K., et al. Peptide geroprotectors: reduced mortality. Bull Exp Biol Med, 133(5), 440–443 (2002).

11. Khavinson, V. K. Thymic peptides and age-related diseases. Front Aging Neurosci, 4, 35–41 (2012).